Ginkgo bioworks stock prediction.

Based on short-term price targets offered by seven analysts, the average price target for Ginkgo Bioworks Holdings, Inc. comes to $3.38. The forecasts range from a low of $1.25 to a high of $6.00 ...Ginkgo Bioworks Holdings Stock (NYSE:DNA), Analyst Ratings, Price Targets, Predictions. Analysts publish ratings and price targets on most stocks. Benzinga ...Feb 7, 2023 · 2. Ginkgo Bioworks. Ginkgo Bioworks (DNA 5.80%) is also a holding in the Ark Innovation ETF and the Ark Genomic Revolution ETF. The company is a leader in cell programming technology that's used ... Ginkgo Bioworks Holdings Inc. analyst ratings, historical stock prices, earnings estimates & actuals. DNA updated stock price target summary.The average price target for Ginkgo Bioworks Holdings is $3.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $7.00 ,the lowest forecast is $1.50. The average price target represents 144.76% Increase from the current price of $1.43.

Contact Us U.S. markets close in 28 minutes S&P 500 +26.05(+0.57%) Dow 30 +272.05(+0.76%) Nasdaq +74.18(+0.52%) Russell 2000 1,852.18 +43.16(+2.39%) Crude Oil 74.32 -1.64(-2.16%) Gold 2,089.10... Real time Ginkgo Bioworks (DNA) stock price quote, stock graph, news & analysis.

Fiscal Q3 2023 ended 9/30/23. Reported on 11/8/23. Get the latest Ginkgo Bioworks (DNA+) real-time quote, historical performance, charts, and other financial information to help you make more ...

Among her various holdings in this high-growth area, Prime Medicine (PRME 11.02%) and Ginkgo Bioworks Holdings (DNA 10.85%) stand out as two of the most promising companies within her portfolios ...Is Ginkgo Bioworks a stock worth buying? When the stock began trading in September 2021, its valuation was around $15 billion. Today, it has a market capitalization of just $3.2 billion.BOSTON, March 1, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2022.1. Ginkgo Bioworks. Down by 67% from a year ago, Ginkgo Bioworks ( DNA -7.32%) is a biotech growth stock that has a solid chance of being a favorite pick during the next bull market. While it isn ...

Forward momentum convinced Wood to buy more than 3 million shares of Archer Aviation stock last week. Now, Ark Invest's stake in the up-and-coming air taxi provider is more than 3 times the size ...

Ginkgo Bioworks ( DNA 10.85%) is your classic high-risk, high-reward investment. The cell programming company isn't generating great results right now, its …

The average price target for Ginkgo Bioworks Holdings is $3.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $7.00 ,the lowest forecast is $1.50. The average price target represents 144.76% Increase from the current price of $1.43.All information and data on the website are for reference only and no historical data shall be considered as the basis for predicting future trends. Information ...The current price Ginkgo Bioworks Holdings (DNA) is trading at is $1.43, which is within the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. …On May 10, Ginkgo Bioworks will report earnings from Q1. Analysts predict losses per share of $0.085. Go here to track Ginkgo Bioworks stock price in real-time ahead of earnings.All information and data on the website are for reference only and no historical data shall be considered as the basis for predicting future trends. Information ...The current Ginkgo Bioworks Holdings [ DNA] share price is $1.43. The Score for DNA is 19, which is 62% below its historic median score of 50, and infers higher risk than normal. DNA is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.As a member of the SPAC class of 2021, Ginkgo Bioworks ( NYSE: DNA) stock has seen its fair share of pummeling over the last few years. From an all-time high at ~$16 to the stock's current price ...

Is Ginkgo Bioworks a stock worth buying? When the stock began trading in September 2021, its valuation was around $15 billion. Today, it has a market capitalization of just $3.2 billion.The Ginkgo Bioworks stock price fell by -3.50% on the last day (Wednesday, 22nd Nov 2023) from $1.43 to $1.38. During the last trading day the stock fluctuated 8.82% from a day low at $1.36 to a day high of $1.48. The price has risen in 5 of the last 10 days but is still down by -7.38% for this period. Volume has increased on the last day by ...Sep 21, 2021 · So what. Initiating coverage on Ginkgo Bioworks, Sriharsha Pappu, an HSBC analyst, assigned a buy rating on the stock and a $14 price target. According to TheFly.com, Pappu believes that the ... Presentation and Q&A session scheduled for post-market on Wednesday, March 1, 2023. BOSTON, Feb. 22, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for …٤ رمضان ١٤٤٤ هـ ... ... outlook Analyzing cell engineering revenues Conclusion ABOUT US ... Ginkgo Bioworks Stock | Not Looking Good. 5.6K views · 8 months ago ...BOSTON, Sept. 9, 2021 /PRNewswire/ -- Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced the launch of Ayana Bio to enable a ...Fiscal Q3 2023 ended 9/30/23. Reported on 11/8/23. Get the latest Ginkgo Bioworks (DNA+) real-time quote, historical performance, charts, and other financial information to help you make more ...

BOSTON, Sept. 27, 2023. BOSTON, Sept. 27, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug ...

Nov 21, 2023 · Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a -272.3% profit margin. Year-over-year quarterly sales growth most recently was -16.6%. Analysts expect adjusted earnings to reach $-0.442 per share for the current fiscal year. Feb 17, 2023 · Last year was not a good one for Ginkgo Bioworks’ stock price, which dropped 80%. Ginkgo’s business model is that it wants to be the Apple (NASDAQ:AAPL) App Store of biotech, the one-stop-shop ... Ginkgo Bioworks Holdings Inc. analyst ratings, historical stock prices, earnings estimates & actuals. DNA updated stock price target summary. Price target ... Based on analysts projections #DNA is expected to experience a positive growth trajectory over the next year. The current average DNA price ...GREENFIELD, Ind. and BOSTON, April 11, 2022 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a leading global animal health company, and Ginkgo Bioworks, the leading horizontal ...Octarine Bio, a synthetic biology company developing new sustainable bio-based ingredients, and Ginkgo Bioworks ... Here's a complete rundown of Wall Street's 2024 stock market predictions.Simply Wall St Published November 13, 2023 Source: Shutterstock The analysts covering Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA) delivered a dose of …Last year was not a good one for Ginkgo Bioworks’ stock price, which dropped 80%. Ginkgo’s business model is that it wants to be the Apple (NASDAQ:AAPL) App Store of biotech, the one-stop-shop ...Why Ginkgo Bioworks isn't a Buffett stock today. Warren Buffett tends to invest in businesses that have highly consistent earnings, low-cost operations, and, above all, sustainable competitive ...Mark Massaro’s Buy rating for Ginkgo Bioworks Holdings (DNA) is mainly due to several significant factors. Firstly, DNA has recently announced a new RNA therapeutics deal with Pfizer, which is ...

r/ginkgobioworks: Subreddit for news & discussion of Ginkgo Bioworks — the organism company — $DNA — all welcome — free, frank, & diverse …

Ginkgo Bioworks (DNA 8.53%) is a biotech unlike any other, and it's no surprise why it's consistently attracting the attention of bigwig portfolio managers like Cathie Wood. Wood's confidence in ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Rwanda Biomedical Centre (RBC) today announced a one-year pathogen monitoring ...Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programing and biosecurity, today announced the sale of shares of its Class A common stock ...The 7 analysts offering 12-month price forecasts for Ginkgo Bioworks Holdings Inc have a median target of 3.00, with a high estimate of 7.00 and a low estimate of 1.25.Jun 23, 2023 · As a member of the SPAC class of 2021, Ginkgo Bioworks ( NYSE: DNA) stock has seen its fair share of pummeling over the last few years. From an all-time high at ~$16 to the stock's current price ... "Ginkgo is committed to harnessing the power of programmable biology to enable sustainable food production and food security worldwide," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. "We look forward to partnering with Bayer and other innovative companies, and to bringing more applications on to Ginkgo's expanded …Among her various holdings in this high-growth area, Prime Medicine (PRME 11.02%) and Ginkgo Bioworks Holdings (DNA 10.85%) stand out as two of the most promising companies within her portfolios ...Ginkgo Bioworks. 13 Apr, 2023, 07:00 ET. Collaboration with University of Wisconsin Professors Krishanu Saha (PI) and Christian Captini (co-PI) to discover novel and improved GD2 CAR designs to ...733.3157. 57.0849. -288.9. -6,916. Get the detailed quarterly/annual income statement for Ginkgo Bioworks Holdings, Inc. (DNA). Find out the revenue, expenses and profit or loss over the last ... Feb 7, 2023 · 2. Ginkgo Bioworks. Ginkgo Bioworks (DNA 5.80%) is also a holding in the Ark Innovation ETF and the Ark Genomic Revolution ETF. The company is a leader in cell programming technology that's used ... The current Ginkgo Bioworks Holdings [ DNA] share price is $1.43. The Score for DNA is 19, which is 62% below its historic median score of 50, and infers higher risk than normal. DNA is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.

Jason R. Kelly, who serves as the Director, CEO, and Founder of Ginkgo Bioworks Holdings, sold a total of 200,000 shares for $360,400. After this transaction, …Ginkgo Bioworks Holdings (DNA – Research Report) received a Sell rating and a $1.25 price target from Goldman Sachs analyst Matthew Sykes today. The company’s shares closed yesterday at $1.68.The projected annual revenue for Ginkgo Bioworks Holdings Inc - is 377MM, a decrease of 3.37%. ... With coverage of over 75,000 listed companies on all major stock exchanges, ...Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and ...Instagram:https://instagram. orbital computertodays top stock gainerslizivsp for seniors Find the latest Ginkgo Bioworks Holdings, Inc. DNA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range investment ratingDec 1, 2023 · Based on short-term price targets offered by seven analysts, the average price target for Ginkgo Bioworks Holdings, Inc. comes to $3.38. The forecasts range from a low of $1.25 to a high of $6.00 ... cheap stocks that will blow upbest technical indicators for forex 1. Ginkgo Bioworks. Down by 67% from a year ago, Ginkgo Bioworks ( DNA -7.32%) is a biotech growth stock that has a solid chance of being a favorite pick during the next bull market. While it isn ... cggr etf People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.Gingko Bioworks (NYSE:DNA) is bringing this science to the next level by introducing the power of AI to its toolkit. Ginkgo Bioworks promises that they can design and test microorganisms cheaper ...